Latest news
Rhythm Pharmaceuticals' RM-718 shows positive Phase 2 signal in acquired hypothalamic obesity - DealroomDealroom · Wed, 05 Aug 2026 08:01:44 GMTRM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 07:37:44 GMTRhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewswireGlobeNewswire · Tue, 04 Aug 2026 20:01:00 GMTAfter FDA approval, Rhythm's IMCIVREE logs more than 400 U.S. start forms - Stock TitanStock Titan · Tue, 04 Aug 2026 11:01:00 GMTRhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 10:55:00 GMT